tnm001
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Oct 25, 2022 (NCT05630573)
Timeline
Indications
Mechanism of action
- RSV F-proteinINHIBITOR
RSV F-protein inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06710925 | Phase 3 | Nov 30, 2024 | Chongqing Medical University, Guangzhou Trinomab Biotech Co., Ltd., Sichuan University |
| NCT06083623 | Phase 2/Phase 3 (Phase 3) | Oct 6, 2023 | Chongqing Medical University, Guangzhou Trinomab Biotech Co., Ltd., Sichuan University |
| NCT05630573 | Phase 1/Phase 2 (Phase 2) | Oct 25, 2022 | Guangzhou Trinomab Biotech Co., Ltd., Sichuan University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Guangzhou Trinomab Biotech Co., Ltd. | Government | 3 | 3 | 2 | 2022 |
| Sichuan University | Academic/Hospital | 3 | 0 | 2 | 2022 |
| Chongqing Medical University | Academic/Hospital | 2 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1